Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lopinavir + ritonavir + hydroxychloroquine
- Development stage
- Discontinued
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination therapy consisting of lopinavir, ritonavir, and hydroxychloroquine that was investigated for the treatment of COVID-19, particularly in the early stages of the pandemic. This triple therapy combines two different mechanisms of action: - **Lopinavir/ritonavir**: Lopinavir is an HIV-1 protease inhibitor that was hypothesized to inhibit the SARS-CoV-2 main protease (3CLpro or Mpro). Ritonavir is co-administered to boost lopinavir levels by inhibiting CYP3A4 metabolism. - **Hydroxychloroquine**: An autophagy inhibitor that alkalinizes phagolysosomes, potentially impairing viral uncoating and cellular fusion. It may also have immunomodulatory effects by decreasing the production of proinflammatory cytokines. Clinical trials, including the WHO Solidarity Trial, found that this combination produced little or no reduction in mortality for hospitalized COVID-19 patients compared to standard care.
- Brand names
- PlaquenilKaletra
- Other names
- triple therapy
02
Targets
CYP3A4 (Cytochrome P450 3A4)Mpro (3C-like proteinase of SARS-CoV-2)
Beyond the preview
Go deeper on lopinavir + ritonavir + hydroxychloroquine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lopinavir + ritonavir + hydroxychloroquine.